Literature DB >> 12103372

Resection of advanced thoracic malignancies requiring cardiopulmonary bypass.

Ara A Vaporciyan1, David Rice, Arlene M Correa, Garrett Walsh, J B Putnam, Stephen Swisher, Roy Smythe, Jack Roth.   

Abstract

OBJECTIVES: Patients with malignancies involving cardiac structures have limited therapeutic options and significant risk of mortality. The decision to offer radical palliative or curative resection must be made only after consideration of the substantial surgical risks. The purpose of this retrospective study was to determine the feasibility and benefits of resection with cardiopulmonary bypass (CPB) of metastatic or non-cardiac primary malignancies extending directly into or metastasizing to the heart in select patients. Our results were examined to assess the risks and benefits of such radical therapy.
METHODS: We retrospectively reviewed patient charts and identified all patients with malignancies involving the cardiac chamber or great vessels (excluding renal carcinomas with caval extension) or with substantial cardiac compression who had undergone resection with CPB at The University of Texas M.D. Anderson Cancer Center between January 1995 and July 2000. We evaluated demographic data, symptomatology, tumor characteristics, and outcomes.
RESULTS: Nineteen patients (six males and 13 females; median age of patients, 47 years; age range, 17-67 years) were included in the study. Eleven patients underwent surgery with curative intent, and eight underwent surgery with palliative intent. Seventeen patients had tumors that required CPB because their tumors directly involved the heart and/or great vessels (nine sarcomas, seven epithelial carcinomas, and one unclassified), and two patients (both with sarcomas) required CPB to relieve tumor tamponade. The technique included CPB (n=5), CPB with diastolic arrest (n=12), and CPB with hypothermic circulatory arrest (n=2). Five patients underwent concomitant pneumonectomy, and three underwent lobectomy. Two patients (11%) died in the hospital after resection with palliative intent. Of the 11 patients who underwent resection with curative intent, ten (91%) had complete resections. The median time in the intensive care unit was 5.3 days (range, 0-37 days) and the median length of hospital stay was 17.2 days (range, 0-107 days). Major complications occurred in 11 patients (58%); the most common major complications were pneumonia (n=7 patients), mediastinal hematoma (n=4 patients), and acute respiratory distress syndrome (n=2 patients). The median follow-up duration was 27 months. The overall 1- and 2-year survival rates were 65 and 45%, respectively.
CONCLUSIONS: Extensive thoracic tumors involving cardiac structures can be resected with acceptable risk. When resection was performed with curative intent, excellent 1- and 2-year cumulative survival rates were achieved. Although resection with palliative intent was associated with greater mortality rates, some patients survived for 1 and 2 years. The use of CPB in selected patients with thoracic malignancies should be considered, especially when complete resection can be achieved.

Entities:  

Mesh:

Year:  2002        PMID: 12103372     DOI: 10.1016/s1010-7940(02)00204-x

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

1.  Flexible bronchoscopic excision of a tracheal mass under extracorporeal membrane oxygenation.

Authors:  Jae Jun Kim; Seok Whan Moon; Yong Hwan Kim; Si Young Choi; Seong Cheol Jeong
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 2.  Surgery for malignant lesions of the chest which extensively involved the mediastinum, lung, and heart.

Authors:  Yugo Tanaka; Daisuke Hokka; Hiroyuki Ogawa; Nahoko Shimizu; Takeshi Inoue; Hiroshi Tanaka; Yutaka Okita; Yoshimasa Maniwa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-05-24

3.  Extended resections for the treatment of patients with T4 stage IIIA non-small cell lung cancer (NSCLC) (T4N0-1M0) with or without cardiopulmonary bypass: a 15-year two-center experience.

Authors:  Dimitrios Filippou; Athanasios Kleontas; Vasilios Tentzeris; Christos Emmanouilides; Stavros Tryfon; Sofia Baka; Ioanna Filippou; Kostas Papagiannopoulos
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

4.  Resection of thoracic malignancies infiltrating cardiac structures with use of cardiopulmonary bypass.

Authors:  Rawa Arif; Florian Eichhorn; Klaus Kallenbach; Philipp Seppelt; Arjang Ruhparwar; Hendrik Dienemann; Matthias Karck
Journal:  J Cardiothorac Surg       Date:  2015-06-25       Impact factor: 1.637

Review 5.  Perioperative lung protection.

Authors:  Katherine Marseu; Peter Slinger
Journal:  Korean J Anesthesiol       Date:  2017-05-26

6.  Circulating Tumor Cell Count Can Be a Useful Prognostic Factor in Lung Resection via Cardiopulmonary Bypass.

Authors:  Masaki Hashimoto; Yoshitomo Okumura; Fumihiro Tanaka; Kazue Yoneda; Teruhisa Takuwa; Nobuyuki Kondo; Seiki Hasegawa
Journal:  Case Rep Oncol       Date:  2017-02-15

7.  [Experiences of cardiopulmonary bypass in the treatment of locally advanced pulmonary malignant tumors].

Authors:  Yong Luan; Qingwei Tan; Xiaoming Bian
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-03

8.  Extracorporeal membrane oxygenation (ECMO)-assisted intratracheal tumor resection and carina reconstruction: A safer and more effective technique for resection and reconstruction.

Authors:  Yang Qiu; Qiao Chen; Wei Wu; Shixin Zhang; Meng Tang; Ya Chen; Chao Zhang; Ni Zhou; Nan Jiang; Jianping Feng; Mei Xia; Haidong Wang
Journal:  Thorac Cancer       Date:  2019-02-19       Impact factor: 3.500

9.  Management of refractory hypoxemia during elective extracorporeal support for complex tracheal resection.

Authors:  Ranjani Venkataramani; Alexander E Lewis; Ivette Perez-Munoz; Neal S Gerstein
Journal:  Saudi J Anaesth       Date:  2022-01-04

Review 10.  Extracorporeal support for pulmonary resection: current indications and results.

Authors:  Petra Rosskopfova; Jean Yannis Perentes; Hans-Beat Ris; Fabrizio Gronchi; Thorsten Krueger; Michel Gonzalez
Journal:  World J Surg Oncol       Date:  2016-02-02       Impact factor: 2.754

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.